Skip to content
CancerIndex

Publication

Limited incremental prognostic value of pretreatment MRI and 18F-piflufolastat PET intensity metrics in grade group ≥ 3 prostate cancer.

Nuttaphon Aleenajitpong, Rory L Cochran, Sarah Mercaldo, Harleen Kaur, Nabih Nakrour, Isabela C S Lima, Mukesh G Harisinghani

Abdominal radiology (New York)Sep 16, 2026PMID 42747479doi:10.1007/s00261-026-05796-4 Journal ArticlepubmedProvenance
Source
PubMed
Retrieved
Sep 18, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-PUBMED-20260918-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

BACKGROUND: Multiparametric MRI (mpMRI) and prostate-specific membrane antigen (PSMA) PET are increasingly used for pretreatment staging of prostate cancer, but their incremental prognostic value for progression-free survival (PFS) beyond clinical variables remains uncertain. OBJECTIVE: To evaluate…

Read on PubMed

Linked entities

Linked entities (1)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Candidate 1

Curated evidence

Evidence citing this paper (0)

Data not yet available

No curated evidence item cites this publication.